

UK NEQAS for H&I Scheme 2B - Crossmatching by Flow Cytometry

T-CELL AND B-CELL FLOW CYTOMETRY RESULTS OF SAMPLE 2B01/2018 OS PC (COMPARED TO LOCAL NEGATIVE CONTROL)

DISPATCHED ON 27 FEBRUARY :

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A31; B8, B51; Cw7, Cw-; DR15, DR17; DQ2, DQ6

Summary of Results											
T-cells					B-cells						
Total tested	41	41	41	42	37	38	38	39			
Positive	9	1	1	29	5	1	2	38			
Negative	25	40	39	8	30	36	36	0			
Equivocal	7	0	1	5	2	1	0	1			
NT	7	7	7	6	8	7	7	6			
% Positive	22.0%	2.4%	2.4%	69.0%	13.5%	2.6%	5.3%	97.4%			
% Negative	61.0%	97.6%	95.1%	19.0%	81.1%	94.7%	94.7%	0.0%			
% Equivocal	17.1%	0.0%	2.4%	11.9%	5.4%	2.6%	0.0%	2.6%			
Consensus	Not Assessed	Negative	Negative	Not Assessed	Negative	Negative	Negative	Positive			
HLA Antibody Specificity (Defined By CDC)	A1	B12	B7	A1 A11 DR15	A1	B12	B7	A1 A11 DR15			
Lab No.	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Date Received	Date Tested	Comments
112	NT	NT	NT	NT	NT	NT	NT	NT	07-Mar	07-Mar	Low cell viability
115	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	28-Feb	01-Mar	
117	Negative	Negative	Negative	Positive	NT	Negative	Negative	Positive	01-Mar	01-Mar	Poor replication
118	Negative	Negative	Negative	Positive					28-Feb	28-Feb	
119	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	27-Feb	28-Feb	
120	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	28-Feb	01-Mar	
122	Positive	Negative	Positive	Positive	Negative	Negative	Negative	Positive	28-Feb	01-Mar	
130	NT	NT	NT	NT	NT	NT	NT	NT	28-Feb	02-Mar	Technical issues.
133	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	01-Mar	02-Mar	
138	Negative	Negative	Negative	Negative					01-Mar	01-Mar	
139	Positive	Negative	Equivocal	Positive	Equivocal	Negative	Negative	Positive	02-Mar	02-Mar	
143	Negative	Negative	Negative	Equivocal					01-Mar	01-Mar	
144	Negative	Negative	Negative	Positive	Positive	Negative	Negative	Positive	28-Feb	01-Mar	
145	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	28-Feb	01-Mar	
147	Equivocal	Negative	Negative	Positive	Equivocal	Negative	Negative	Positive	01-Mar	01-Mar	
149	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	28-Feb	01-Mar	
154	Equivocal	Negative	Negative	Positive	Negative	Negative	Negative	Positive	01-Mar	02-Mar	Delayed delivery
157	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	28-Feb	28-Feb	
159	Equivocal	Negative	Negative	Positive	Negative	Negative	Negative	Positive	28-Feb	01-Mar	
160	Negative	Negative	Negative	Equivocal	Negative	Negative	Negative	Positive	28-Feb	01-Mar	
163	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Positive	28-Feb	01-Mar	
167	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	28-Feb	01-Mar	
169	NT	NT	NT	NT	NT	NT	NT	NT			No results returned
176	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	01-Mar	02-Mar	
189	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	28-Feb	01-Mar	
190	NT	NT	NT	NT	NT	NT	NT	NT	02-Mar	NT	Delayed delivery
191	Equivocal	Negative	Negative	Positive	Negative	Negative	Negative	Positive	28-Feb	01-Mar	
193	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	28-Feb	01-Mar	
194	Equivocal	Negative	Negative	Positive	Negative	Negative	Negative	Positive	28-Feb	28-Feb	Poor cell count
195	Negative	Positive	Negative	Negative	Negative	Equivocal	Negative	Positive	02-Mar	02-Mar	We received samples with aggregated cells
201	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	28-Feb	28-Feb	
209	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	27-Feb	01-Mar	
218	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Equivocal	08-Mar	08-Mar	Poor viability and limited numbers of B-cells and we would request an additional sample for testing
220	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Positive	28-Feb	01-Mar	
235	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	28-Feb	28-Feb	
238	Equivocal	Negative	Negative	Equivocal	Negative	Negative	Negative	Positive	28-Feb	01-Mar	
240	Positive	Negative	Negative	Positive	Positive	Positive	Negative	Positive	01-Mar	01-Mar	
246	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	28-Feb	28-Feb	
252	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	01-Mar	01-Mar	
260	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	01-Mar	01-Mar	
262	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	28-Feb	01-Mar	
271	NT	NT	NT	NT	NT	NT	NT	NT	07-Mar	07-Mar	Low viability and cell count
276	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	01-Mar	06-Mar	Few cells
293	Negative	Negative	Negative	Equivocal	Negative	Negative	Negative	Positive	01-Mar	01-Mar	
297	Equivocal	Negative	Negative	Equivocal	Negative	Negative	Negative	Positive	28-Feb	28-Feb	
341	NT	NT	NT	NT	NT	NT	NT	NT			No results returned
351	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	03-Mar	03-Mar	
392	NT	NT	NT	NT	NT	NT	NT	NT			No results returned

UK NEQAS for H&I Scheme 2B - Crossmatching by Flow Cytometry

T-CELL FLOW CYTOMETRY RESULTS OF SAMPLE 2B01/2018 OS PC (COMPARED TO LOCAL NEGATIVE CONTROL)

DISPATCHED ON 27 FEBRUARY 2018

Lab No.	Serum 1 cytometer reading	Serum 2 cytometer reading	Serum 3 cytometer reading	Serum 4 cytometer reading	Negative control (local)	Positive control (local)	Strong positive (local)	Weak positive (local)	Positive result value	Cytometer reading units	Viability (%)
112	-	-	-	-	-	-	-	-		Median log channel	0
115	272	223	217	356	273	331			>40 linear channel shift	Median linear channel shift	
117	4.96	4.57	4.87	6.62	4.48	51.17			Ratio (RMF) >1.3	Median log channel	95
118	213	192	191	266	172	736			238 (172+66)	Median linear channel	90
119	0.215	0.164	0.169	0.512	0.166	4.6			ratio Pos >1.285 B-line 1.285-1.45	Mnlx	90
120	1.51	1.05	1.12	3.38	52	1553.5			Ratio >1.6	Median	100
122	20	10	16	48	10		74	26	3SD	Geomean linear value	98
130	-	-	-	215	135	442			40	Mean channel shift	100
133	0.4	0.1	0.2	1.4	0.3	62.6			2SD	MFI	99
138	0.1	0.09	0.04	0.1	0	0.85			>0.2	D Value Kolmogorov-Smirnov Statistic	
139	0.9	0.3	0.4	2.54	0.43	57			>1.5 local neg control	MFI	80
143	6	0	0	-	7	146			More than 40 channel shift	Mean channel shift	80
144	1.24	0.91	1.16	1.82	714	3.88			1.6	Median/Ratio	
145	0.641	0.247	0.371	1.342	0.517	39.8			2SD of the ratio	Median log channel	92
147	173	134	132	206	120	568			>40 linear channel shift	Linear channel	100
149	0.328	0.236	0.282	0.479	0.279	113			2SD	Median log channel	83
154	118	62	78	257	77	1857			Median >150% of negative	MFI	
157	167	159	153	238	177	3632			2SD (cut off 205)	Median log channel	98
159	40	-22	-4	133	159	476			40	Mean fluorescence	95
160	6.7	6.6	5.8	17.3	6.7	299			>15.4 (Neg +2SD)	Mean linear channel	
163	3.8	1.2	1.4	20.2	1	13			2.3 (ratio above)	Geomean linear channel	100
167	206	131	144	216	172	15104			2SD	Median log channel	93
169											
176	0.29	0.02	0.02	0.58	0	0.99			0.4	MFI Shift	
189	16.09	0.34	1.36	3.22	1.36	96.68			>5%	%	90
190	-	-	-	-	-	-			-	-	-
191	33	5.6	5.5	86	0	371			>30	MFI	98
193	14.67	5.73	6.03	40.04	5	181.8			2.4x local neg control	Ratio	
194	0.758	0.312	0.337	1.2	0.312	15.8			>1.2		
195	242	279	231	257	199	462			Test/Neg control ≥1.3	Median log channel	80
201	0.584	0.446	0.479	0.763	0.448	20.7			S/NK ≥2.0	x-mean	89
209	418	199	210	1750	169	1196				MFI	
218	2.5	1.2	1.2	10.4	-	7.1			Ratio >1.6	Ratio	94
220	105	73.2	75.2	158	75.9	3200			1.2x geometric mean MFI	Geometric mean MFI	
220	7586	1684	2696	31409	1237	261694			6000 above the mean of the neg control	Linear acquisition	93
235	1.84	1	1.3	1.43	1.23	153.3			>2 neg control median log channel	Median log channel	85
238	-	-	-	-	1704	13529			MESF serum/MESF Neg control	MESF	
240	28	18	18	42	17	380			1.2x Neg control	MFI	60
246	1.2	1.05	1.05	2.15	-	6.91			1.75	MFI	93
252	0.9	0.98	1.1	1.4	145	2776			Median ratio ±2SD		65
260	13.87%	7.42%	7.11%	69.91%	5.19%	99.84%			>20% shift	% shift	
262	818	662	617	517	757	19265			2SD	Median channel shift	70
271	-	-	-	-	-	-			-	-	-
276	278	184	196	706	332	13592			>1.25x Neg control	MFI	93
293	4.57	3.85	3.89	7.37	3.62	122			10 channel shift	Channel shift	80
297	120	83	71	118	88	250			1.8x T Neg	MFI	
341											
351	163	141	144	198	138	10752			500	MFI	98
392											

UK NEQAS for H&I Scheme 2B - Crossmatching by Flow Cytometry

B-CELL FLOW CYTOMETRY RESULTS OF SAMPLE 2B01/2018 OS PC (COMPARED TO LOCAL NEGATIVE CONTROL)

DISPATCHED ON 27 FEBRUARY 2018

Lab No.	Serum 1 cytometer reading	Serum 2 cytometer reading	Serum 3 cytometer reading	Serum 4 cytometer reading	Negative control (local)	Positive control (local)	Strong positive (local)	Weak positive (local)	Positive result value	Cytometer reading units	Viability (%)
112	-	-	-	-	-	-	-	-		Median log channel	0
115	409	418	433	633	486	764			>60 linear channel shift	Median linear channel shift	
117	-	8.92	11.43	52.1	10.42	272.1			Ratio (RMF) >1.5	Median log channel	95
119	2.26	1.99	2.31	10.9	1.52	7.8			ratio Pos >1.7	Mnix	90
									B-line 1.7-2.3		
120	1.32	1.06	1.2	4.86	318.5	4401			Ratio >2	Median	100
122	130	79	122.5	606	83.5		393	150	3SD	Geomean linear value	98
130	-	-	-	417	220	430			80-100	Mean channel shift	100
133	0.9	0.3	0.5	19.2	2.9	159.7			2SD	MFI	99
139	6.41	3.57	4.4	47.2	6.46	152			>2 local neg control	MFI	80
143	-	-	-	-	-	-				-	-
144	2.72	2.18	2.17	8.43	1514	4.93			2.6	Median/Ratio	
145	0.485	0.44	0.456	10.5	0.546	53.1			2SD of the ratio	Median log channel	92
147	281	236	243	461	230	445			>60 linear channel shift	Linear channel	100
149	0.908	0.52	0.603	4.66	1.55	148			2SD	Median log channel	83
154	500	233	516	3567	430	5458			Median >200% of negative	MFI	
157	140	170	130	223	144	4040			2SD (cut off 180)	Median log channel	98
159	13	-64	25	229	307	662			100	Mean fluorescence	95
160	47.2	47.3	29.3	143.6	32	541			>104.2 (Neg +2SD)	Mean linear channel	
163	1.9	1	1.2	11.3	1	40			1.7 (ratio above)	Geomean linear channel	100
167	970	560	845	4102	1099	25681			2SD	Median log channel	93
169											
176	0.09	-0.22	0.02	0.94	0	0.91			0.22	MFI Shift	
189	-	-	-	-	40	>40			>5%	%	90
190	-	-	-	-	-	-			-	-	-
191	20.5	17	24.5	128	0	355			>100	MFI	98
193	53.43	34.24	45.92	286.78	31.03	400.5			2.3x local neg control	Ratio	
194	7.345	6.47	5.075	16.4	1.63	102			>4		
195	242	275	218	394	182	1318			Test/Neg control ≥1.6	Median log channel	80
201	2.82	1.79	1.98	5.73	2.16	43.2			S/NK ≥2.5	x-mean	89
209	2996	1934	2108	14009	1906	6199				MFI	
	1.6	1	1.1	7.3		3.3			Ratio >1.7	Ratio	94
218	1241	715	716	2172	1329	6411			1.7x geometric mean MFI	Geometric mean MFI	
220	11063	5740	7371	87911	3338	261725			6000 above the mean of the neg control	Linear acquisition	93
235	5.86	4.09	4.41	1357.7	7.5	2196.8			>12 neg control median log channel	Median log channel	85
238	-	-	-	-	2011	21042			MESF serum/MESF Neg control	MESF	
240	1100	1246	831	1135	719	2220			1.4x Neg control	MFI	60
246	1.37	1	1.11	6.86		28.84			2.5	MFI	93
252	1.1	0.8	5.87	2.6	154	1065			Median ratio ±2SD		65
260	30.21%	18.94%	25.46%	74.57%	25.14%	97.44%			>20% shift	% shift	
262	1515	1172	1148	4078	1518	46621			2SD	Median channel shift	70
271	-	-	-	-	-	-				-	-
276	653	465	692	5076	701	20402			>1.25x Neg control	MFI	93
293	24.3	18.6	17	142	11.3	155			20 channel shift	Channel shift	80
297	182	109	99	788	131	360			2x T Neg	MFI	
341											
351	341	257	283	1357	250	14599			2500	MFI	98
392											